Pictured: Dr Justin Wong and Mr Kurtis Budden (who accepted on behalf of Professor Phil Hansbro) at the Awards Ceremony, March 14, 2019.
Cancer Council NSW has awarded funding to 13 ground-breaking cancer research projects including two to the Centenary Institute – Dr Justin Wong, Head of our Epigenetics and RNA Biology Program for his research ‘Understanding the mechanisms that cause acute myeloid leukaemia’ and Professor Phil Hansbro, Director of the Centenary UTS Centre for Inflammation for his project ‘Could our gut bacteria play a role in lung cancer?’
“We are extremely proud to
announce another round of extraordinary projects in 2019. We are confident
these projects will provide incredible value to cancer patients and continue to
push our progress towards a cancer free future,” said Dr Jane Hobson, Research
Grants Manager at Cancer Council NSW.
Funds have been awarded to
projects deemed through peer review to be of the highest scientific merit; and
through consumer review to be of the most value to the community supporting
the full Cancer Council NSW media release
Learn more about the work of Professor Phil Hansbro and Dr Justin Wong.
The Centenary Institute has collaborated with fellow medical research institute, the Hudson Institute in Victoria, to develop a novel model system for accurately monitoring tumour stage and immune cells involvement.
Head of Centenary’s Liver Enzymes in Metabolism and Inflammation Program, Professor Mark Gorrell, was involved in the research project.
Ovarian cancer develops slowly and the immune system is crucial in controlling the tumour. In this particular study, the researchers modified ovarian cancer cells so they glowed in a way that can be seen in live laboratory mice models – enabling counts of tumour cells and immune cell subsets when each tumour is removed.
This system has allowed the researchers to learn new information on tumour growth, as well as discover which immune cells are in the tumour.
The researchers plan to apply the model to other cancers, including liver cancer.
Read the full study online in scientific journal Cancers.
Learn more about how Professor Gorrell’s team at Centenary is working to help develop a new liver disease test.
Centenary Institute scientists have discovered dozens of new likely targets for a particular enzyme (FAP) that is within most tumours; paving the way for the future development of safer and more effective cancer therapies, including liver, lung, skin, colorectal and pancreatic cancers.
Instead of affecting and interacting with just collagen, the researchers have used new technologies to identify 37 molecules which FAP likely modifies.
Co-lead author, Dr Hui Emma Zhang from the Centenary Institute, says this study not only reaffirms the value of FAP in cancer research, but it also provides new avenues through which scientists can target tumour growth.
“Given FAP is fairly unique to damaged cells when compared to healthy cells, the findings from our research will enhance the initial identification and imaging of tumours, as well as provide a safer and more targeted pathway through which anti-cancer therapies can be delivered,” says Dr Zhang.
See the full media release.
Read Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics in Molecular and Cellular Proteomics.
Pictured: A human liver tumour (large pale cells) surrounding a peninsular of stromal cells (dense blue), with FAP molecules stained dark brown.
Think you know about inflammation? Think again. Redness, swelling, muscle aches…that’s not even the half of it. Chronic inflammation is a key driver of diseases, such as cancer, cardiovascular disease and autoimmune diseases. Read more.
What does a stubbed toe or a splinter in a finger have to do with your risk of developing Alzheimer’s disease, suffering a heart attack or succumbing to colon cancer? More than you might think. Related articles below:
Inflammation Research Foundation – Cellular Inflammation: The Secret Killer (Article).